Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309941 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Gu-Shun Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms, Liver Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Visceral metastasis is an important predictor for poor outcomes in prostate cancer, however, the prognostic significance surrounding the specific sites of visceral metastasis remains unclear. The aim of this study was to evaluate the impact of different visceral metastatic sites on survival in patients with prostate cancer.
Methods
We identified patients with metastatic prostate cancer between January 1, 2010 and December 31, 2023 using the TriNetX database. Patients were divided into 4 cohorts according to their specific metastatic sites: lung metastases, brain metastases, liver metastases, and bone metastases. Survival analysis was calculated using the Kaplan-Meier method and Cox regression models.
Results
In total, 59,875 patients diagnosed with metastatic prostate cancer were identified, with 39,495 (65.2%) having bone metastases, 7,573 (12.5%) lung metastases, 5,240 (8.7%) brain metastases, and 7,567 (12.5%) liver metastases. The median overall survival was 44.4 months for patients with bone metastases, 31.9 months for lung metastases, 9.6 months for brain metastases, and 10 months for liver metastases. Lung metastases were associated with an improved survival when compared with liver and brain metastases. For patients with two visceral metastatic sites or concomitant bone metastases, liver metastases were related to worse outcomes. Asian patients experienced better OS than Caucasian and African American patients in visceral metastatic prostate cancer.
Conclusion
Patients with lung metastases experienced better survival outcomes in prostate cancer with only one visceral metastatic site. Liver metastases were associated with worse outcomes when there were two visceral metastatic sites combined or concomitant bone metastases. Asian patients displayed improved survival rates when compared with both Caucasian and African American patients in visceral metastatic prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medicine and Nursing, Hungkuang University, Taichung, Taiwan.
- Jenteh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
ORCID-Profile: Gu-Shun Lai, Shian-Shiang Wang
Zitieren
APA
Lai, G. S., Chen, C. S., Cheng, J. C., Li, J. R., Yang, C. K., Lin, C. Y., Hung, S. C., Chiu, K. Y., & Wang, S. S. (2024). Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0309941
Vancouver
Lai GS, Chen CS, Cheng JC, Li JR, Yang CK, Lin CY, et al. Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0309941
BibTeX
@article{Lai2024,
author = {Lai, Gu-Shun and Chen, Chuan-Shu and Cheng, Jason Chia-Hsien and Li, Jian-Ri and Yang, Cheng-Kuang and Lin, Chia-Yen and Hung, Sheng-Chun and Chiu, Kun-Yuan and Wang, Shian-Shiang},
title = {Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309941}
}
EUVIMED